FDA D.I.S.C.O. Burst Edition: Approval of Opdivo (nivolumab) for resected esophageal or gastroesophageal junction cancer with residual disease who have received chemoradiotherapy and Rybrevant (amivantamab-vmjw) for locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations
Release Date:
Opdivo (nivolumab) for patients w/ resected esophageal/GEJ cancer w/ residual pathologic disease who have received neoadjuvant chemoradiotherapy & Rybrevant (amivantamab-vmjw) for adult patients with locally advanced/metastatic NSCLC w/ epidermal growth factor receptor exon 20 insertion mutations
FDA D.I.S.C.O. Burst Edition: Approval of Opdivo (nivolumab) for resected esophageal or gastroesophageal junction cancer with residual disease who have received chemoradiotherapy and Rybrevant (amivantamab-vmjw) for locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations